ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits. Eligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU). The primary endpoint is favorable functional outcome at 90 days, defined as modified Rankin Scale (mRS) 0-2 or return to pre-stroke mRS. Endpoint assessment at 90 days is performed by blinded assessors (PROBE design). Secondary outcomes include early neurological deterioration, recurrent stroke, delirium, mortality, health-related quality of life, healthcare utilization, and cost-effectiveness. A mixed-methods process evaluation examines feasibility, acceptability, and implementation aspects of the ambulatory care model.
Stroke unit treatment in Germany is currently organized as multi-day inpatient care regardless of stroke severity. However, a substantial proportion of patients with acute ischemic stroke or transient ischemic attack present with non-disabling or fully regressed neurological deficits and may not require prolonged inpatient monitoring. At the same time, demographic changes and increasing stroke incidence in older populations challenge inpatient stroke unit capacity and resource allocation. International experience with structured outpatient TIA and minor stroke clinics suggests that ambulatory management models may provide comparable clinical safety while reducing hospital utilization. However, randomized evidence for such models within the German healthcare system is lacking. The ARTIFICE trial evaluates a structured ambulatory stroke unit care model designed to provide comprehensive same-day multiprofessional assessment and initiation of secondary prevention while maintaining patient safety. The study investigates whether this ambulatory care approach can represent a medically safe and resource-efficient alternative to conventional inpatient stroke unit treatment in selected older patients. In addition to clinical effectiveness, the study examines patient-reported outcomes, healthcare utilization, cost-effectiveness, and implementation aspects to inform future health services planning.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Enrollment
400
Structured ambulatory stroke care model providing same-day neurological assessment, diagnostic work-up, therapeutic evaluation, and multidisciplinary case review, followed by discharge home if medically appropriate.
Standard inpatient stroke unit treatment according to national clinical guidelines, including hospital-based monitoring, diagnostic evaluation, and initiation of secondary prevention.
Heidelberg University Hospital
Heidelberg, Germany
RECRUITINGFavorable Functional Outcome at 90 Days
Favorable functional outcome defined as modified Rankin Scale (mRS) score 0-2 or return to pre-stroke mRS level, assessed by blinded outcome assessors.
Time frame: 90 days (±14 days) after randomization
Early Neurological Deterioration
Increase in National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points compared to baseline.
Time frame: Within 7 days after randomization
Recurrent Stroke
Occurrence of recurrent ischemic stroke, hemorrhagic stroke, or transient ischemic attack during follow-up.
Time frame: Up to 90 days after randomization (primary safety observation period)
Delirium Occurrence
Occurrence of delirium assessed using the Confusion Assessment Method (CAM).
Time frame: Within 7 days after randomization
All-Cause Mortality
Death from any cause.
Time frame: 90 days and 12 months after randomization
Functional Status
Change in Barthel Index score from baseline to 90 days.
Time frame: Baseline and 90 days
Stroke Impact
Change in SIS-16 score from baseline to 90 days.
Time frame: Baseline and 90 days
Mobility
Change in Timed Up and Go Test (TUG) time from baseline to 90 days.
Time frame: Baseline and 90 days
Health-Related Quality of Life
Change in EQ-5D-5L index value and EQ visual analogue scale (EQ-VAS) from baseline to 90 days.
Time frame: Baseline and 90 days
Healthcare Utilization
Use of outpatient, inpatient, and nursing care services assessed by questionnaire.
Time frame: Up to 90 days after randomization
Serious Adverse Events
Occurrence of serious adverse events including unplanned hospitalization or death.
Time frame: Up to 90 days after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.